Cargando…

ZHER2 Affibody as a Good Candidate for Detection of Metastatic Prostate Cancer

Detalles Bibliográficos
Autores principales:	Nazari, Mahboobeh, Radmanesh, Ramin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Avicenna Research Institute 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377404/ https://www.ncbi.nlm.nih.gov/pubmed/34484647 http://dx.doi.org/10.18502/ajmb.v13i3.6366

Ejemplares similares

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule (188)Re-ZHER2:41071
por: Liu, Yongsheng, et al.
Publicado: (2022)

Preclinical Evaluation of (99m)Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
por: Oroujeni, Maryam, et al.
Publicado: (2021)

Expression of CDX2 in metastatic prostate cancer
por: Guerrieri, C., et al.
Publicado: (2019)

Texture and color enhancement imaging for detecting colorectal adenomas: Good, but not good enough
por: Wang, Ying, et al.
Publicado: (2022)

Affibody-Binding Ligands
por: Barozzi, Annalisa, et al.
Publicado: (2020)

MicroRNA let-7a: a novel therapeutic candidate in prostate cancer
por: Wu, Xiao-Qin, et al.
Publicado: (2014)

Cross Talk between the Ketogenic Diet and Metastatic Prostate Cancer Cells
por: Okechukwu, Chidiebere Emmanuel
Publicado: (2022)

Chemotherapy regimens for metastatic nonsmall cell lung cancer: Generating good quality data is important before challenging evidence
por: Kaur, Harpreet, et al.
Publicado: (2016)

FDG PET/CT in Prostate Cancer: A Valuable Method to Detect the Primary and Metastatic Tumor Sites and to Monitor Cancer Response to Hormonal Therapy
por: Hinev, Alexander, et al.
Publicado: (2012)

Tumour-Induced Osteomalacia in Metastatic Prostate Carcinoma
por: Tatachar, Sreevatsa, et al.
Publicado: (2023)

Prostate volume and its influence on clinical parameters in prostate cancer detection
por: Stephan, Carsten, et al.
Publicado: (2023)

Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies
por: Dillinger, Thomas, et al.
Publicado: (2022)

Prokaryotic expression of antibodies and affibodies
por: Fernández, Luis Angel
Publicado: (2004)

Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas
por: Shastri, Y M, et al.
Publicado: (2008)

Affibody Functionalized Beads for the Highly Sensitive Detection of Cancer Cell-Derived Exosomes
por: Sayyadi, Nima, et al.
Publicado: (2021)

Reply: Faecal tumour pyruvate kinase M2: not a good marker for detection of colorectal adenomas
por: Haug, U, et al.
Publicado: (2008)

Radiomics-clinical nomogram for response to chemotherapy in synchronous liver metastasis of colorectal cancer: Good, but not good enough
por: Yan, Han, et al.
Publicado: (2022)

Prostate cancer antigen 3 and genetic risk score as markers for the detection of prostate cancer in the Chinese population
por: Wei, Han-Min, et al.
Publicado: (2015)

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)

Are dogs good at spotting movement? Velocity thresholds of motion detection in Canis familiaris
por: Lõoke, Miina, et al.
Publicado: (2020)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

A model of the natural history of screen-detected prostate cancer
por: Metcalfe, C, et al.
Publicado: (2006)

Affibody molecules as engineered protein drugs
por: Frejd, Fredrik Y, et al.
Publicado: (2017)

Good news for Kerala
por: Gupta, Prabha Nini, et al.
Publicado: (2016)

Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
por: Gibbons, Jacqueline A.
Publicado: (2015)

Imaging of Metastatic Cancer Cells in Sentinel Lymph Nodes using Affibody Probes and Possibility of a Theranostic Approach
por: Tsuchimochi, Makoto, et al.
Publicado: (2019)

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT
por: Sörensen, Jens, et al.
Publicado: (2016)

Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer
por: Alhuseinalkhudhur, Ali, et al.
Publicado: (2020)

Unravelling the origin of SARS-CoV-2: is the model good?
por: Frutos, R., et al.
Publicado: (2021)

RESEARCH IN INDIA: NOT GOOD ENOUGH?
por: Patel, Vikram
Publicado: (2001)

Religion and health: not always good
por: Pasternak, Jacyr
Publicado: (2020)

Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy
por: Gabriele, Federica, et al.
Publicado: (2023)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

Comment on “How Good is Your Model Fit? Weighted Goodness‐of‐Fit Metrics for Irregular Time Series”
por: Zaadnoordijk, Willem J.
Publicado: (2022)

Molecular design of radiocopper-labelled Affibody molecules
por: Tolmachev, Vladimir, et al.
Publicado: (2018)

Affibody Molecules as Targeting Vectors for PET Imaging
por: Tolmachev, Vladimir, et al.
Publicado: (2020)

Positional goods and the underfunding of public health
por: Hemenway, David
Publicado: (2021)

Which Nutritional Factors Are Good for HDL?
por: Yanai, Hidekatsu, et al.
Publicado: (2018)

Reply to: Religion and health: not always good
por: Akerman, Marco, et al.
Publicado: (2020)

Vaccines: A universal public good()
por: Padrós Selma, Jaume
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qahmqqt4mc6fceeli7j015i4d5